Targeting cancer with Click Chemistry

Less than 1% of administered drugs make it to their desired location in the body.

Let's do better

Next generation tumor-targeting

Our proprietary Click Activated Protodrugs Against Cancer (CAPAC^®) platform is a pre-targeting approach, capturing payloads at the tumor via in-vivo click chemistry, a 2022 Nobel Prize-winning technology.

We are the first company to use click chemistry in patients.

Here's how

CAPAC is modular

CAPAC separates the binder from the payload and reunites them at the tumor.

Clickable binder

Binds selectively to the tumor

Clickable payload

Either a radioisotope or cancer drug that is inert until it clicks with the binder at the tumor

Activation

When the systemically administered clickable payload reaches the clickable binder at the tumor, a click chemistry reaction takes place. For radioisotopes, this locks the radioisotope at the tumor; for chemotherapy this activates the payload.

A new approach

Changing what's possible

We separate tumor targeting from the payload, and rely on chemistry, not biology, for activation. This leads to maximum active payload at the tumor and lower systemic toxicity than has been previously possible.

CAPAC is designed to expand the scope of potential targets and widen the therapeutic window of antibody drug conjugates (ADCs) and targeted radiopharm approaches. CAPAC has been validated in the clinic and we are rapidly advancing novel therapies for patients with limited effective treatment options.

Our platform

Latest News

media

Tackling ADCs 1% problem

"Three years after demonstrating the first-ever in vivo use of click chemistry by safely delivering 12 times the standard dose of doxorubicin directly to tumors, Shasqi is again pushing boundaries. Its CAPAC platform, which initially relied on intratumoral injections, now targets CEACAM5, a cell-surface antigen overexpressed in lung, gastric, pancreatic, colorectal, esophageal/HNSCC, and cervical cancers, with a systemically administered MMAE. Early data in rats reveal a 300-fold improvement in tolerability of their activated MMAE protodrug compared with conventional MMAE at 50x the dose."

‍

Read the full article by Brian Buntz here

‍

Together we can transform cancer treatment

Ready to help us develop the future of cancer therapies?

Join our team

Interested in exploring a collaboration?

Partner with us